Last Name | Name | Awards | Contact | |
---|---|---|---|---|
Berkland | Cory Berkland | 5 | ||
Beyerinck | Ronald Arthur Beyerinck | 2 | ||
Flynn | Maria Flynn | 4 | Message | |
Newbold | David N. Newbold | 2 | ||
Dormer | Nathan H Dormer | 11 | Message | |
Dumbauld | David Dumbauld | 2 | ||
Singh | Milind Singh | 4 | Message |
Phase 1 SBIR
PROJECT SUMMARY Current approaches to treat sensorineural hearing loss (SNHL) in newborns suffering from congenital cytomegalovirus (CMV) infection rely on off-label, systemic antiviral therapy requiring high dose, long duration treatment with demonstrated hematologic toxicity, carcinogenicity, and teratogenicity. Furthermore, it is unknown whe...
Phase 2 SBIR
? DESCRIPTION (provided by applicant): New treatment options are needed for inner ear disorders including Meniere's disease, sensorineural hearing loss, autoimmune inner ear disease, and tinnitus. In the absence of FDA-approved drugs, physicians use improvised treatments, including the administration of off-label steroids, which lack safety a...
Phase 2 SBIR
DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...
Phase 2 SBIR
DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...
Phase 2 SBIR
DESCRIPTION (provided by applicant): New treatment options are needed for inner ear disorders including Meniere's disease, sensorineural hearing loss, autoimmune inner ear disease, and tinnitus. In the absence of FDA-approved drugs, physicians use improvised treatments, including the administration of off-label steroids, which lack safety and ef...
Phase 2 SBIR
DESCRIPTION (provided by applicant): New dosage forms are needed to address the shortcomings of current practice with regard to administration of medications to pediatric populations. Specifically, in the absence of pediatric-specific products - formulations that are both palatable (to ensure compliance) and titratable (to meet the weight/surfac...
Phase 2 SBIR
DESCRIPTION (provided by applicant): New dosage forms are needed to address the shortcomings of current practice with regard to administration of medications to pediatric populations. Specifically, in the absence of pediatric-specific products - formulations that are both palatable (to ensure compliance) and titratable (to meet the weight/surfac...
Phase 2 SBIR
DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...
Phase 1 SBIR
Vaccination is a particularly powerful weapon in the fight against wide-spread livestock disease. Commercially available vaccines, however, are often difficult and costly for livestock producers to use properly, leaving individual animals - and by extension the global food supply - at risk. More specifically, many vaccines on the market today re...
Phase 2 SBIR
DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs are projected to have high clinical efficacy, they are often rejected in the early stages of re...